TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06858813: A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

Sponsor: AbbVie · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 232 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$6,817,272

Rescue Site Savings

+$4,492,488

Unlock Full NCT06858813 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06858813 Rescue Dossier →